Online inquiry

IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11413MR)

This product GTTS-WQ11413MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11413MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12500MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ13643MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ3058MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ9563MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ11563MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ10389MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ15988MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ9636MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW